Free accessCase reportFirst published online 2010-11
Evolution and suppression of HBV strains with multidrug resistance to lamivudine,adefovir dipivoxil and entecavir in a patient with chronic hepatitis B
Here, we report a case of multidrug resistance in a patient with chronic hepatitis B. The patient sequentially received lamivudine, adefovir dipivoxil and entecavir, and subsequently developed single-, double- and triple-drug-resistant HBV strains. We consider this case report important because it documents, for the first time, that triple-drug-resistant HBV strains identified in a clinical setting were suppressible by lamivudine add-on adefovir dipivoxil when tenofovir disoproxil fumarate was not available.
References
1.
European Association for the Study of the Liver.EASL Clinical Practice Guidelines: management of chronic hepatitis B.J Hepatol2009; 50: 227–242.
LokA.S., ZoulimF., LocarniniS.Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.Hepatology2007; 46: 254–265.
4.
PapatheodoridisG.V., ManolakopoulosS., DusheikoG., ArchimandritisA.J.Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.Lancet Infect Dis2008; 8: 167–178.
5.
ZoulimF., PerrilloR.Hepatitis B: refections on the current approach to antiviral therapy.J Hepatol2008; 48 Suppl 1: S2–S19.
6.
ZoulimF., LocarniniS.Hepatitis B virus resistance to nucleos(t)ide analogues.Gastroenterology2009; 137: 1593–1608.
7.
LocarniniS.Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure.Hepatol Int2008; 2: 147–151.
8.
BrunelleM.N., JacquardA.C., PichoudC.Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.Hepatology2005; 41: 1391–1398.
9.
VilletS., PichoudC., VilleneuveJ.P., TrepoC., ZoulimF.Selection of a multiple drug-resistant hepatitis B virus strain in a liver transplanted patient.Gastroenterology2006; 131: 1253–1261.
10.
VilletS., OllivetA., PichoudC.Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.J Hepatol2007; 46: 531–538.
11.
ShimJ.H., SuhD.J., KimK.M.Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.Hepatology2009; 50: 1064–1071.
12.
SantantonioT., FasanoM., DurantelS.Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B.Antivir Ther2009; 14: 557–565.
13.
InoueJ., UenoY., YutaW.Emergence of multiple drug-resistant mutants of hepatitis B virus with long-term lamivudine and adefovir bitherapy.Hepatology2009; 50 Suppl 4: 518A.
14.
XuD., FuJ., JinL.CD4+CD25+ regulatory T cells in circulation and liver actively influence the antiviral immune response and disease progression in patients with hepatitis B.J Immunol2006; 177: 739–747.
15.
LiuY., ZhongY., ZouZ.Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B.J Clin Virol2010; 47: 243–247.
16.
VilletS., BillioudG., PichoudC.In vitro characterization of viral fitness of therapy-resistant hepatitis B variants.Gastroenterology2009; 136: 168–176.
17.
LiuY., WangC., XuD.Analysis of hepatitis B virus drug-resistant mutations for 2000 patients with chronic hepatitis B virus in China.Hepatol Int2009; 3: 111.
